CIK 0001798749
- Emerging growth company
Jade Biosciences, Inc.
Sign in to watch- Ticker
- JBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831377888
- Phone
- +1 781-312-3013
- Business address
- 221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aerovate Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-22 | Pigot Timothy CHIEF COMMERCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +66,586 | 66,586 | ||
| 2024-01-22 | Verwijs Marinus CHIEF TECHNOLOGY OFFICER | Grant or award · Stock Option (Right to Buy) | +66,586 | 66,586 | ||
| 2024-01-22 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (Right to Buy) | +66,586 | 66,586 | ||
| 2024-01-22 | Gillies Hunter CHIEF MEDICAL OFFICER | Grant or award · Stock Option (Right to Buy) | +66,586 | 66,586 | ||
| 2024-01-22 | Dake Benjamin T SEE REMARKS | Grant or award · Stock Options (Right to Buy) | +66,586 | 66,586 | ||
| 2024-01-22 | Eldridge George A SEE REMARKS | Grant or award · Stock Options (Right to Buy) | +66,586 | 66,586 | ||
| 2024-01-17 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +4,000 | $1.74 | $7K | 7,251 |
| 2024-01-17 | Gillies Hunter CHIEF MEDICAL OFFICER | Sale 10b5-1 | −4,000 | $19.50 | $78K | 3,251 |
| 2024-01-17 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,000 | 6,027 | ||
| 2024-01-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +1,400 | $1.74 | $2K | 3,009 |
| 2024-01-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise 10b5-1 | +3,200 | $2.14 | $7K | 6,209 |
| 2024-01-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −2,126 | $18.67 | $40K | 4,083 |
| 2024-01-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −2,474 | $19.57 | $48K | 1,609 |
| 2024-01-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −900 | 14,208 | ||
| 2024-01-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −500 | 9,588 | ||
| 2024-01-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −500 | 11,394 | ||
| 2024-01-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,200 | 36,108 | ||
| 2024-01-05 | NIVEN RALPH CHIEF SCIENTIFIC OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,500 | 43,232 | ||
| 2024-01-02 | Santel Donald J Director | Grant or award · Stock Option (Right to Buy) | +2,889 | $13.49 | $39K | 2,889 |
| 2024-01-02 | Dable Habib J Director | Grant or award · Stock Option (Right to Buy) | +2,964 | $13.49 | $40K | 2,964 |
Page 9 of 16 · 315 trades